BioCreatrix:
Pioneering Breakthroughs in Precision Medicine and Immunology
At BioCreatrix, we have been at the forefront of technological and scientific advancements, driving innovation in genomic precision medicine and immunology. Our focus lies in the development of groundbreaking diagnostics, preventative measures, and early intervention therapies.
Rather than inventing single products in isolation, our approach centers around the strategic utilization of three cutting-edge, multi-disciplinary technological platforms. This streamlined, versatile framework allows us to continuously develop a diverse portfolio of novel medical devices, testing kits, pharmaceuticals, and vaccines in a seamless, well-established manner.
By leveraging these integrated technological foundations, we are able to rapidly translate the latest scientific discoveries into practical, easy-to-validate solutions. This agile, platform-centric strategy empowers us to stay ahead of the curve, delivering transformative products that address the evolving needs of the global healthcare landscape.
Through our unwavering commitment to scientific excellence and technological innovation, BioCreatrix is proud to be a driving force in the advancement of personalized medicine, early disease detection, and targeted immunotherapies. Our goal is to continue pioneering breakthroughs that elevate the standard of care and improve patient outcomes worldwide.
01
Personalized Cancer Vaccines
At BioCreatrix, we are pioneering the development of personalized cancer vaccines. Our approach uses each patient's unique tumor profile to create a customized vaccine that trains the immune system to recognize the identified tumor neoantigens.
Our personalized cancer vaccine platform leverages advanced genomic analysis and machine learning to identify the neoantigens that are unique to each and every individual. We manufacture personalized vaccine pools containing these neoantigens as Investigational New Drugs (IND). At Clinical Trials, the personalized vaccine pools will be administered to recruited subjects.
Together with other target therapies or Immuno-oncology drugs, we believe the forefront approach of using personalized cancer vaccines will alleviate immunosuppression and improve anti-tumour effectiveness.
02
CAR-NK IND Pipelines
In addition to our work in personalized cancer vaccines, we are also advancing 6 IND pipelines of novel CAR-NKs immunotherapies. The patented design of specific CARs enable the engineered NK cells to mediate specific killing of tumour cells by tri-specific tumour anchoring target antigens per IND pipeline.
The dual mechanisms of action of CBiolab's CAR-NK cells enable NK cells to retain their natural cytotoxic activity against tumour cells and can be activated through a CAR dependent or CAR independent manners.
03
Early Screening Tests
Beyond oncology, we are also developing innovative point-of-care tests for the early detection of Alzheimer's disease. Our proprietary technology utilizes a simple blood draw to measure specific biomarkers associated with the early stages of Alzheimer's pathology.
By enabling earlier diagnosis, our Alzheimer's screening tests have the potential to transform clinical practice and patient outcomes. Earlier detection allows for earlier intervention, which is critical given the progressive nature of Alzheimer's disease. Our tests could empower patients and clinicians to take action sooner, leading to better disease management and potentially slowing cognitive decline.
We are committed to advancing this transformative technology and making it accessible to healthcare providers and patients around the world. Our goal is to revolutionize Alzheimer's disease diagnosis and pave the way for more effective treatments and improved quality of life for those affected by this devastating condition.